LiquiVent

LiquiVent®

Perflubron, see there.
Mentioned in ?
References in periodicals archive ?
Alliance will continue to investigate other applications for LiquiVent using supplies that have been transferred to its San Diego, California facilities.
Alliance is investigating the use of LiquiVent, a perfluorochemical liquid that spreads easily through the airways, as a safe vehicle for delivery of genes and other drugs directly into the lungs.
Efficacy data from the study revealed that PLV with LiquiVent did not meet either the primary study endpoint for improvement in 'ventilator free days' or the secondary endpoint of improvement in 28-day mortality.
Patient enrollment in an international Phase 2-3 study with LiquiVent was completed in December 2000.
Efficacy data from the study revealed that PLV with LiquiVent did not meet either the primary study endpoint for improvement in "ventilator free days" or the secondary endpoint of improvement in 28-day mortality.
LiquiVent is an intrapulmonary "liquid ventilation" agent for treatment of acute lung injury and acute respiratory distress syndrome.
LiquiVent is an oxygen-carrying liquid drug (perflubron) being developed under U.
In regard to LiquiVent, we are compiling and analyzing the data from our recently completed Phase 2-3 clinical study, and we anticipate that preliminary results will be available this spring.
Additional events expected in fiscal 2001 include completion of enrollment in the LiquiVent Phase 2-3 study, completion of enrollment in the Oxygent Phase 3 cardiac surgery study, announcement of top-line data from each of these studies, and submission of a Marketing Authorization Application for Oxygent in Europe.
OPTISON(R), the only approved perfluorochemical-based ultrasound contrast agent, is a welcome addition to our family of PFC products in late-stage clinical development, which includes Imavist, Oxygent, and LiquiVent.
The Phase 2-3 pivotal trial is a randomized, controlled study being conducted in North America and Europe to evaluate the safety and efficacy of LiquiVent for adult ALI and ARDS patients.
has agreed to sell to Alliance raw materials (perflubron) for up to $3 million that Alliance can use for its LiquiVent and Oxygent(TM) products.